Palvella - Pioneering Therapies For Rare Genetic Skin Diseases With Over $1 Bln Market Opp

 It's been a banner year so far for Palvella Therapeutics Inc. (PVLA), which recently debuted on the Nasdaq, with its share price soaring by as much as 117% year-to-date.

This clinical-stage biopharmaceutical company is exclusively focused on developing transformational therapies for rare diseases with no FDA-approved treatments. Its lead product candidate is QTORIN rapamycin, currently under development for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and other serious, functionally debilitating skin diseases driven by the overactivation of the mTOR pathway. The mTOR signaling pathway is a key regulator of cell growth, proliferation, survival, and metabolism.

Ongoing Trials with QTORIN 3.9% Rapamycin Anhydrous Gel:

-- A phase III trial of QTORIN 3.9% Rapamycin Anhydrous Gel for the treatment of microcystic lymphatic malformations (microcystic LMs), dubbed SELVA, is underway. The study is currently enrolling approximately 40 subjects at leading vascular anomaly centers across the U.S. The primary efficacy endpoint is the change from baseline in the overall microcystic LM Investigator Global Assessment (mLM-IGA) at week 24.

Previously, the trial participants were required to be at least 6 years old. Last month, the company announced that it will also include patients ages 3 to 5 years old in the SELVA trial.

Microcystic LMs is a rare, chronically debilitating genetic disease characterized by malformed lymphatic vessels that protrude through the skin, continuously leak lymph fluid (lymphorrhea), and bleed. This often results in recurrent serious infections and cellulitis that can cause hospitalization. Currently, there are no FDA-approved treatments for the more than 30,000 individuals diagnosed with microcystic LMs in the United States.

The company expects to report topline results from the SELVA trial in the first quarter of 2026.

-- QTORIN 3.9% Rapamycin Anhydrous Gel is also being studied in a phase II trial for the treatment of cutaneous venous malformations (cutaneous VMs), dubbed TOIVA. This trial is designed to enroll approximately 15 participants, ages six and older, at leading vascular anomaly centers across the U.S.

The TOIVA study will assess the safety and tolerability based on the incidence and severity of adverse events. It will also evaluate multiple measures of efficacy, including change from baseline to week 12 in clinician and patient global impression assessments as well as assessments of specific individual clinical manifestations that contribute to disease burden.

Cutaneous VMs are a rare genetic disease characterized by dysfunctional veins within the skin. These malformations can cause substantial morbidity and functional impairment, significantly impacting quality of life. They are associated with severe bleeding, ulceration, thrombosis, and other potential complications. In the U.S., there are estimated to be over 75,000 individuals diagnosed with cutaneous VMs with no FDA-approved treatments.

The company expects to report data from the TOIVA study in the fourth quarter of this year.

According to the company, there is a significant commercial opportunity for QTORIN rapamycin in treating Microcystic Lymphatic Malformations and Cutaneous Venous Malformations, with the sales potential for both the diseases estimated to be over $1 billion.

Cash position

Palvella ended the year 2024 with cash and cash equivalents of approximately $80.0 million.

Palvella Therapeutics shares began trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol "PVLA", following a reverse merger with Pieris Pharmaceuticals Inc. (PIRS).

https://www.rttnews.com/3519965/palvella-pioneering-therapies-for-rare-genetic-skin-diseases-with-over-1-bln-market-opportunity.aspx